Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
A Texas judge ruled that the Food and Drug Administration wrongly approved mifepristone in 2000 and accused it of doing a rush job. Here's what really went down. -
There's a nationwide shortage of the antibiotic amoxicillin. It is making it harder for doctors to treat strep throat.
-
In a long anticipated decision, the Food and Drug Administration approved an over-the-counter version of naloxone spray, a generic form of the opioid overdose treatment called Narcan.
-
The U.S. Food and Drug Administration late last year got more leverage over pharmaceutical companies that received accelerated approvals for their drugs. How will the agency use its new powers?
-
The FDA announced the supply troubles in the fall. Four months later, the medication remains hard to get and could stay that way until the spring
-
The cost of prescription drugs have been a political issue for years. If Congress passes the Reduce Inflation Act, a provision would allow Medicare, for the first time, to negotiate drug prices.
-
The Biden administration says help is on the way to address the nationwide baby formula shortage. How would the Defense Production Act, a legal vestige of the Cold War era, help?
-
Paxlovid and molnupiravir have been authorized for emergency use to keep COVID-19 patients out of the hospital, but don't expect to be able to go to your usual pharmacy and get them.
-
There's a new, heavily mutated COVID-19 variant called omicron. Scientists tell us what's known so far about it, what's not yet known, and what this all means for public health.
-
Immediately after the Food and Drug Administration authorized Pfizer's vaccine, the company delivered fewer doses than its government contract projected. Federal officials say they didn't know why.
